InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

Stock Information for MariMed Inc

Loading

Please wait while we load your information from QuoteMedia.